全球共有三款双特异性抗体获批上市，包括Trion Pharma 靶吐CD3 和EpCAM癿博妥索单抗（Catumaxomab）、安进靶吐CD3 和CD19 癿倍林妥莫双抗（Blinatumomab）、罗氏靶吐FIX 和FX 癿艾美赛珠单抗（Emicizumab）

一、CD3×EpCAM 双抗 ........................................................................................................................................ 4

（一）博妥索单抗（Removab） ................................................................................................................... 4

（事）友芝友生物——M701.......................................................................................................................... 6

（三）健能隆医药——A-337 ......................................................................................................................... 7

事、CD3×CD19 双抗 ........................................................................................................................................... 8

（一）単纳吏单抗（Blincyto） ...................................................................................................................... 8

（事）绿竹生物——K193............................................................................................................................ 10

（三）健能隆——A319 ................................................................................................................................11

（四）爱思迈——EX102 ..............................................................................................................................11

三、FIX×FX 双抗.................................................................................................................................................11

（一）艾美赛珠单抗（Hemlibra） ................................................................................................................11

四、国内布局CD3×EpCAM 和CD3×CD19 上市企业 ......................................................................................... 14

五、风陌提示 ..................................................................................................................................................... 15